Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of Sulpiride Tablets
CTR20263806Phase 3Active
- Sponsor
- Shouguang Fukang Pharmaceutical
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sulpiride in schizophrenia, major depressive disorder (MDD), sponsored by Shouguang Fukang Pharmaceutical. Started Oct 2026; status: active.
02
Drugs
sulpiride
03
Conditions
schizophreniamajor depressive disorder (MDD)
Beyond the preview
Go deeper on CTR20263806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263806.